文献速递免疫规划妇幼与学校卫生

妊娠期乙肝疫苗接种的接种率与安全性:疫苗安全数据链研究

Uptake and safety of Hepatitis B vaccination during pregnancy: A Vaccine Safety Datalink study.
PubMed 文献 · Vaccine · 2018-09-05

该回顾性队列研究基于疫苗安全数据链(VSD)2004至2015年活产妊娠数据,评估孕期乙肝疫苗(HepB)接种频率及与母婴安全结局的关联。在超过65万例妊娠中,HepB接种率为2.1/1000妊娠(n=1399),多发生于妊娠最初5周;接种组中不足3%存在需接种的高危ICD-9码,与未接种组相似。孕期HepB暴露与妊娠期高血压、妊娠期糖尿病、子痫前期/子痫、剖宫产、早产、低出生体重或小于胎龄儿均无显著关联。

要点

  • 孕期HepB接种率为2.1/1000妊娠,多在妊娠最初5周内接种。
  • 接种组中不足3%存在HBV感染高危ICD-9码,与未接种组相似。
  • 孕期HepB暴露与所评估的母婴不良结局均无显著关联。

核心结论

  • 多数接受孕期HepB接种的妇女并无接种的高危指征。
  • 接受孕期HepB接种的妇女或其子代中,未观察到所评估不良结局的风险增加。

研究设计与样本

  • 回顾性队列研究,纳入疫苗安全数据链(VSD)2004至2015年活产妊娠。
  • 纳入标准为12-55岁女性,从孕前6个月至产后6周连续参保于VSD整合卫生系统。
  • 比较HepB暴露妊娠与其他疫苗暴露及无疫苗暴露妊娠。
  • 使用ICD-9码识别孕前一年内或孕期HBV感染高危条件。

主要发现

  • 研究期间超过650,000例妊娠中,HepB接种率为2.1/1000妊娠(n=1399),常见于妊娠最初5周内。
  • HepB暴露组中不足3%具有指示需要HepB的高危ICD-9码,与HepB未接种组相似。
  • 孕期HepB暴露与妊娠期高血压、妊娠期糖尿病、子痫前期/子痫、剖宫产、早产、低出生体重或小于胎龄儿之间无显著关联。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Hepatitis B virus (HBV) infection acquired during pregnancy can pose a risk to the infant at birth that can lead to significant and lifelong morbidity. Hepatitis B vaccine (HepB) is recommended for anyone at increased risk for contracting HBV infection, including pregnant women. Limited data are available on the safety of HepB administration during pregnancy. OBJECTIVES: To assess the frequency of maternal HepB receipt among pregnant women and evaluate the potential association between maternal vaccination and pre-specified maternal and infant safety outcomes. METHODS: We examined a retrospective cohort of pregnancies in the Vaccine Safety Datalink (VSD) resulting in live birth outcomes from 2004 through 2015. Eligible pregnancies in women aged 12-55 years who were continuously enrolled from 6 months pre-pregnancy to 6 weeks postpartum in VSD integrated health systems were included. We compared pregnancies with HepB exposure to those with other vaccine exposures, and to those with no vaccine exposures. High-risk conditions for contracting HBV infection were identified up to one-year prior to or during the pregnancy using ICD-9 codes. Maternal and fetal adverse events were also evaluated according to maternal HepB exposure status. RESULTS: Among over 650,000 pregnancies in the study period, HepB was administered at a rate of 2.1 per 1000 pregnancies (n = 1399), commonly within the first 5 weeks of pregnancy. Less than 3% of the HepB-exposed group had a high-risk ICD-9 code indicating need for HepB; this was similar to the rate among HepB unvaccinated groups. There were no significant associations between HepB exposure during pregnancy and gestational hypertension, gestational diabetes, pre-eclampsia/eclampsia, cesarean delivery, pre-term delivery, low birthweight or small for gestational age infants. CONCLUSIONS: Most women who received maternal HepB did not have high-risk indications for vaccination. No increased risk for the adverse events that were examined were observed among women who received maternal HepB or their offspring.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Groom HC, Irving SA, Koppolu P, et al. Uptake and safety of Hepatitis B vaccination during pregnancy: A Vaccine Safety Datalink study. Vaccine. 2018. PMID: 30194002. doi:10.1016/j.vaccine.2018.08.074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。